Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company misled investors regarding the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][2]. Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information about the differences between its Nanobody drug SLK and traditional monoclonal antibodies, including: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - SLK's Nanobody structure does not provide a clinical benefit over BIMZELX's monoclonal structure [2]. - The supposed increased tissue penetration of SLK does not translate to improved clinical efficacy [2]. - Consequently, the positive statements made by the company regarding SLK's superiority lacked a reasonable basis [2]. Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3]. Next Steps for Investors - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff, representing other class members in the litigation [4]. - Investors can remain absent class members and still be eligible for recovery without taking any action [4]. Company Background - Robbins LLP, the firm leading the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Legal Proceedings - A class action lawsuit has been filed against MoonLake, alleging that the company misled investors regarding the trial design and efficacy data of SLK prior to the announcement of the trial results [1][2][3]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [3]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy being substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, representing a 90% decrease, which analysts described as a "worst case outcome" [2][6]. Product Comparison - SLK's commercial prospects were heavily reliant on demonstrating efficacy comparable to or superior to BIMZELX, which is already FDA-approved for the same indication [4]. - The lawsuit claims that MoonLake made false statements regarding the advantages of SLK's Nanobody structure over traditional monoclonal antibodies, asserting that it would lead to superior clinical benefits [5]. Investor Communication - Throughout the class period, MoonLake promoted SLK's structural advantages, claiming it could achieve benefits unattainable by monoclonal antibodies and positioned it as a potential "gold standard" treatment [5]. - The lawsuit alleges that these statements were misleading and that the company failed to disclose critical information about SLK's clinical efficacy [5][6].

LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX. ...

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, impacting investors who purchased its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that during the class period, MoonLake made false or misleading statements regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide superior clinical benefits or efficacy [4]. Stock Performance Impact - Following the announcement of disappointing Phase 3 VELA program results on September 28, 2025, which indicated SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased MoonLake common stock during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history at $7.2 billion in the Enron case [7].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit for securities fraud, alleging that the company made false and misleading statements regarding its drug candidate, sonelokimab (SLK), which led to significant losses for investors [4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against MoonLake Immunotherapeutics for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased securities between March 10, 2024, and September 29, 2025, are encouraged to contact the firm before December 15, 2025 [2]. - The lawsuit claims that MoonLake misled the market about the superiority of SLK over other monoclonal antibodies, despite lacking proven advantages [4]. Group 2: Impact on Investors - Following the announcement of a Phase 3 trial result deemed "disastrous" by analysts, MoonLake's shares lost almost 90% of their value [4]. - The company's public statements were characterized as false and materially misleading throughout the class period, resulting in damages for investors when the truth was revealed [4].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab, leading to significant financial losses after disappointing trial results were announced [7]. Allegation Details - The lawsuit claims that MoonLake promoted sonelokimab as superior to competing monoclonal antibodies while failing to disclose that it targeted the same molecules as UCB's BIMZELX and did not demonstrate proven superiority [7]. - Following the announcement of Phase 3 trial results on September 28, 2025, which showed that sonelokimab did not match the efficacy of BIMZELX, MoonLake's stock price dropped nearly 90%, resulting in substantial losses for investors [7]. Next Steps - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. Company Information - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across state and federal courts [5].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of federal securities laws due to false and misleading statements regarding the company's drug candidate, sonelokimab (SLK) [1][2]. Company Allegations - The lawsuit claims that MoonLake Immunotherapeutics misled investors by promoting SLK as superior to competing monoclonal antibodies, specifically failing to disclose that SLK targeted the same molecules as UCB's BIMZELX and did not demonstrate proven superiority [2]. - Following the announcement of Phase 3 results on September 28, 2025, which indicated that SLK did not match the efficacy of BIMZELX, MoonLake's stock plummeted nearly 90%, resulting in significant investor losses [2]. Legal Proceedings - The lawsuit is filed in the Southern District of New York under the case name Bridgewood v. MoonLake Immunotherapeutics et al., and it represents all individuals who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [3]. - Investors who acquired MoonLake stock during the specified period may seek to be appointed as lead plaintiffs, with a deadline for such motions set for December 15, 2025 [4].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement of the trial results [3]. Legal Implications - Investors in MoonLake are encouraged to seek additional information regarding potential legal options due to the investigation and the significant stock price decline [1][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation, with a strong track record of recovering substantial amounts for clients [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices, following a significant drop in the company's stock price after a trial report [1][2]. Investigation Details - The investigation focuses on whether MoonLake has engaged in unlawful business practices that may have led to investor losses [1][2]. - The firm is encouraging investors who suffered losses to contact them for discussions regarding their legal rights [1][3]. Stock Performance - On September 29, 2025, MoonLake Immunotherapeutics reported that its VELA-2 trial did not achieve statistical significance due to unexpected results in the placebo group, leading to a drastic stock decline of 89.9% on the same day [6].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics regarding potential securities fraud or unlawful business practices [1] - MoonLake reported disappointing results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [1] - Following the trial results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [1] Company Overview - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX [1] - The company is involved in the development of immunotherapeutic treatments, specifically focusing on sonelokimab [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past [2]